Oxford university is to launch a £10m research programme in medical marijuana with venture capital funding, in the hope of developing treatments for pain, cancer and inflammatory disease.
Kingsley Capital Partners, a private equity business based in London, has set up a company, Oxford Cannabinoid Technologies, to fund the research. Eight scientists at the university will investigate different medical applications of marijuana in their labs.
“Medical cannabis is already helping patients with some of the most distressing conditions across the world,” said Neil Mahapatra, managing partner of Kingsley. “However, research into the specific pathways and mechanisms that create this benefit is limited and long overdue. We hope our strategic partnership with Oxford will support the development of innovative new therapies to help millions of people.”
Read more here
Date posted: 16 March 2017
Article tag: Kingsley Capital Partners Article tag: Oxford Cannabinoid Technologies
Share